What is the recent guidelines on heart failure with preserved ejection fraction
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive, authoritative content from multiple major textbooks. Let me compile the full answer.
Heart Failure with Preserved Ejection Fraction (HFpEF): Current Guidelines & Management
Definition & Epidemiology
HFpEF is defined as heart failure with LVEF ≥50% (some guidelines use ≥45%). It accounts for more than half of all HF cases in older adults, with higher prevalence in women. Hypertension is the most common antecedent (60–80% of cases). The condition is now understood as a multifactorial systemic illness involving aging, inflammation, multimorbidity, metabolic dysfunction, and genetic predisposition — not merely a disorder of diastolic dysfunction. — Braunwald's Heart Disease
Diagnosis
Diagnosis requires:
- Symptoms and signs of HF
- LVEF ≥50% (or ≥45% by some criteria)
- Evidence of elevated LV filling pressures (invasive or non-invasive) or structural changes (LV hypertrophy, LA enlargement)
- Elevated natriuretic peptides (BNP/NT-proBNP)
The H2FPEF and HFA-PEFF scoring systems aid diagnosis when the diagnosis is uncertain. A careful search for mimics (amyloidosis, hemochromatosis, sarcoidosis, Fabry's disease, hypertrophic cardiomyopathy, pericardial disease) is essential since these require distinct management. — Harrison's 2025, Fuster's The Heart 15e
2022 AHA/ACC/HFSA Guideline Highlights
The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure remains the primary reference. Key evidence-based recommendations:
Pharmacological Treatment
1. SGLT-2 Inhibitors ✅ — Class IIa / IIb recommendation; now the cornerstone novel therapy
The most significant recent development:
- EMPEROR-Preserved trial: Empagliflozin reduced the composite of cardiovascular death or HF hospitalization by 21% (HR 0.79; 95% CI 0.69–0.90; P<0.001), and recurrent HF hospitalization by 27% — regardless of diabetes status or LVEF subgroup.
- DELIVER trial: Dapagliflozin showed similar benefits in HFpEF/HFmEF.
- Empagliflozin/dapagliflozin should be considered in all eligible HFpEF patients unless contraindicated. This is the only drug class with robust trial evidence for HFpEF.
— Fuster's The Heart 15e; Harrison's 2025
2. Diuretics — Symptom relief / congestion control
- Loop diuretics (furosemide) are indicated to maintain euvolemia and relieve dyspnea and edema.
- Must be used judiciously — overdiuresis risks prerenal azotemia, hypotension, and syncope due to the stiff, filling-dependent ventricle.
3. Mineralocorticoid Receptor Antagonists (MRAs) — Modest benefit
- TOPCAT trial: Spironolactone failed to reduce the primary composite (CV death, aborted cardiac arrest, HF hospitalization) overall, but reduced HF hospitalization by 17%.
- Post-hoc analysis confined to the Americas showed 18% reduction in the primary outcome (significant), raising confidence in a real benefit.
- Spironolactone can be considered in eligible HFpEF patients, particularly those with EF closer to 45–50%.
4. Sacubitril/Valsartan (ARNi) — Modest/selective benefit
- PARAGON-HF trial (4822 patients, LVEF ≥45%): 13% reduction in primary composite (CV death + HF hospitalization) — narrowly missed significance (P=0.06).
- Greatest benefit in: women, patients with LVEF <57% (mildly reduced range), and those with recent HF hospitalization.
- The PARAGLIDE-HF trial showed significant NT-proBNP reduction vs valsartan alone in patients with EF >40%, with benefits confined to EF ≤60%.
- FDA has approved sacubitril/valsartan across the full EF spectrum, with benefits acknowledged to be greatest in those with LVEF below normal.
- When combined with an MRA, sacubitril/valsartan also reduced rates of renal events.
5. ACE Inhibitors & ARBs — Not recommended as primary therapy
- CHARM-Preserved (candesartan): modest non-significant trend toward reduced HF hospitalization.
- I-PRESERVE (irbesartan): no benefit on mortality or hospitalization.
- PEP-CHF (perindopril): early benefit on hospitalizations attenuated at longer follow-up.
- ACEi/ARBs are useful for comorbidity management (hypertension, CKD, CAD) but not as HF-specific disease-modifying therapy.
6. Beta-Blockers — Not recommended for HFpEF specifically
- No dedicated trial demonstrates benefit in LVEF ≥50%.
- May worsen chronotropic incompetence.
- Useful in specific settings: rate control in atrial fibrillation, management of CAD or hypertension.
- Ivabradine also failed to improve outcomes in HFpEF patients with HR ≥70 bpm.
7. GLP-1 Receptor Agonists — Emerging therapy in obese HFpEF
- Semaglutide (STEP-HFpEF trial) improved quality of life, symptoms, and exercise capacity in obese HFpEF patients, independent of diabetes.
- GLP-1 agonists improve QoL irrespective of diabetes mellitus in obese HFpEF.
- Harrison's 2025
8. Drugs That Did NOT Show Benefit
| Drug | Trial | Outcome |
|---|---|---|
| Digoxin | DIG Ancillary | No effect on mortality/hospitalization |
| Sildenafil (PDE-5 inhibitor) | RELAX | No benefit |
| Nitrates | NEAT-HFpEF | No improvement in exercise capacity |
| Statins | Multiple trials | No specific HFpEF benefit |
| Soluble guanylate cyclase stimulators | SOCRATES | No benefit |
Non-Pharmacological Management (Core Recommendations)
| Intervention | Evidence |
|---|---|
| Blood pressure control to guideline targets | Strong — BP is the dominant modifiable risk factor |
| AF management — rate/rhythm control, anticoagulation | Important — AF worsens outcomes significantly |
| Sodium/fluid restriction | Standard practice |
| Aerobic exercise training | Improves exercise tolerance and QoL (LVEF-HITT trial) |
| Weight loss in obese patients | Caloric restriction + exercise provides additive benefit |
| Comorbidity management | Diabetes, CKD, OSA, anemia/iron deficiency, COPD |
| Ischemia evaluation/revascularization | Consider in patients with CAD |
Special Considerations
Cardiac Amyloidosis (ATTR)
- Wild-type ATTR (ATTRwt) may account for 10–15% of HFpEF in older men.
- Hereditary ATTR (Val122Ile variant) found in 3–4% of African Americans.
- Tafamidis (transthyretin stabilizer) is disease-modifying and reduces mortality in ATTR cardiomyopathy.
- Recognition is critical — management differs substantially from typical HFpEF. — Braunwald's Heart Disease
Atrial Fibrillation
- AF coexists in a large proportion of HFpEF patients and worsens outcomes.
- Aggressive rate control, anticoagulation, and early rhythm restoration (cardioversion/ablation) should be pursued.
HFmEF (EF 40–49%)
- Patients with mildly reduced EF (HFmEF) should be treated similarly to HFrEF — the same four pillars (SGLT-2i, MRA, ARNi, beta-blocker) likely apply given overlapping trial evidence.
Summary: Guideline-Recommended Approach to HFpEF (2022–2025)
| Priority | Intervention |
|---|---|
| Class I | Diuretics for congestion; BP control; exercise; comorbidity management |
| Class IIa | SGLT-2 inhibitors (empagliflozin, dapagliflozin) |
| Class IIb | MRAs (spironolactone); Sacubitril/valsartan (especially EF 45–57%, women) |
| Emerging | GLP-1 agonists in obese HFpEF; tafamidis in ATTR |
| Not recommended | Beta-blockers, ACEi/ARBs, digoxin, PDE-5 inhibitors as HFpEF-specific therapy |
Key takeaway: SGLT-2 inhibitors represent the most significant therapeutic advance in HFpEF management, being the first drug class with robust randomized trial evidence for reducing HF hospitalization in this population. All other proven pharmacologic therapies provide at most modest, selective benefit. Management remains largely symptom-focused with aggressive risk factor and comorbidity control.
Sources: Harrison's Principles of Internal Medicine 22E (2025); Fuster and Hurst's The Heart, 15th Edition; Braunwald's Heart Disease (10e)
This is a shared conversation. Sign in to Orris to start your own chat.